NOTICE OF INTENT TO SOLE SOURCE - Cost Effective Study Estimating Medical Expenses

NOTICE OF INTENT TO SOLE SOURCE

This requirement is for (supplies/services) in which the Government intends to solicit and negotiate with only one-source under the authority of FAR 13.106-1(b) (SAP) and 41 U.S.C. 3304(a)(1). Interested persons may identify their interest and capability to respond to the requirement. This notice of intent is not a request for competitive quotations; however, all responses received within seven (7) days of the issuance of this notice will be reviewed. A determination by the government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. Any response should be emailed to the contract specialist at ycf1@cdc.gov by 2:00 p.m. Eastern Standard Time (EST) on June 30, 2020.

Scope of Work;

The purpose of the proposed study is to estimate the medical expenditure in years before and years after a person is diagnosed with type 2 diabetes by her/his baseline glucose and/or A1c levels.  Longitudinal follow-up data from Optum de-identified Normative Health Information (dNHI) database are the most appropriate data for this analysis as such data contain both health care utilization or cost and glucose measurements for their populations. Glucose measurements from lab tests are needed for the study to establish the baseline risk of type 2 diabetes. Using longitudinal data and grouping persons without diagnosed diabetes by their baseline risk levels of developing type 2 diabetes can overcome the two potential estimate biases available from the current literature by allowing  (1) persons who do or do not develop diabetes and persons with different risk levels of developing type 2 diabetes who have different trajectories in medical expenditures. At least three cohorts of persons without diagnosed diabetes, i.e., those at the low, intermediate, and high-risk level of developing type 2 diabetes shall be created and followed. The follow-up time shall be at least ten years (i.e., 5 years prior and 5 years after the diagnosis of type 2 diabetes) to get a reliable estimate.